Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)

• Status: Recruiting
• Trial end date: 2021-04-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of Ketamine will be compared to the standard sedation in our center, which is Midazolam in combination with Pethidine as analgesia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Universiti Kebangsaan Malaysia Medical Centre
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• Malaysian citizens of who is able to give valid consent

• Patient planned for ERCP (either emergency or elective)

Exclusion Criteria:

• Known hypersensitivity towards Ketamine or Midazolam

• Patient refusal to participate or unable to give consent

• Increased intracranial pressure, acute stroke (<3 months), intracranial haemorrhage (<3 months)

• Uncontrolled hypertension (BP>160/100) and tachycardia (Heart rate >120)

• Acute myocardial infarction, acute coronary syndrome (<3 months)

• Tachyarrythmia

• Pregnancy

• IVDU or substance abuse patient

• Patient with history of hallucination

• Child's Pugh Class C